Please login to the form below

Not currently logged in
Email:
Password:

Actelion announces results

Half-year financial results for Swiss biopharmaceutical company, Actelion, show net revenue is up 27 per cent compared to the same period last year

Half-year financial results for Swiss biopharmaceutical company, Actelion, show net revenue is up 27 per cent compared to the same period last year at CHF 855.2m. The company reported an operating profit of CHF 242.9m compared to CHF 137.2m in H1 2008.

During the six months of 2009, sales of the company's pulmonary arterial hypertension (PAH) drug, Tracleer, reached CHF 739.3m – representing an increase of 23 per cent (in local currencies) compared to the first six months of 2008. The European Commission approved the paediatric dispersible formulation of Tracleer for treatment of PAH in children earlier this month. Sales of Ventavis (also for PAH) increased by 50 per cent in local currencies from CHF 37.9m, in H1 2008 to CHF 61.5m. 

Chief financial officer Andrew Oakley said: "Actelion now expects, unforeseen events excluded, that both total net revenues and cash EBIT [Earnings Before Interest and Tax] - in local currencies - will increase between 16 and 19 per cent for the full year of 2009."

The company reports a pipeline of 10 compounds in clinical development and 25 active projects in drug discovery.

21st July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics